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Abstract
The kynurenine pathway includes several neuroactive compounds, including kynurenic acid,
picolinic  acid,  3-hydroxykynurenine  and  quinolinic  acid.  The  enzymatic  cascade  of  the
kynurenine pathway is tightly connected with the immune system, and may provide a link
between the immune system and neurotransmission. Alterations in this cascade are associated
with  neurodegenerative,  neurocognitive,  autoimmune  and  psychiatric  disorders,  such  as
Parkinson’s  disease,  Huntington’s  disease,  Alzheimer’s  disease,  multiple  sclerosis,
amyotrophic  lateral  sclerosis,  migraine  or  schizophrenia.  This  review  highlights  the
alterations  in  this  metabolic  pathway in  the  physiological  aging  process  and  in  different
disorders. A survey is also presented of therapeutic possibilities of influencing this metabolic
route, which can be achieved through the use of synthetic kynurenic acid  analogues, enzyme
inhibitors or even nanotechnology.
Keywords: kynurenine  pathway,  neurodegeneration,  neuroprotection,  glutamate
excitotoxicity,  Parkinson’s  disease,  Alzheimer’s  disease,  multiple  sclerosis,  migraine,
Huntington’s disease, schizophrenia, amyotrophic lateral sclerosis, picolinic acid, aging
1. Recent data relating to the mechanisms of disorders of the CNS
Chronic  progressive  neurodegenerative  diseases  such  as  Parkinson’s  disease  (PD),
Alzheimer’s  disease  (AD),  Huntington’s  disease  (HD)  and  amyotrophic  lateral  sclerosis
(ALS) are becoming increasingly more prevalent, which may be related to the aging of the
population.  The significance of  neurological  diseases is  highlighted by the fact  that  brain
disorders have been stated to be responsible for around 35% of the total burden of all diseases
in Europe1. Migraine, a common primary headache disorder with an overall prevalence of
16% in  the  adult  population,  is  listed  among  the  20  most  important  causes  of  disability
worldwide2-3.  The  increasing  prevalence,  the  high  socioeconomic  impact  and  the  limited
therapeutic  possibilities  have  generated  considerable  research  interest  in  recent  decades.
Although the various neurodegenerative disorders present distinct clinical symptoms, their
pathomechanisms  share  several  features.  A  long  line  of  evidence  indicates  that
neuroinflammation, mitochondrial disturbances, glutamate (Glu) excitotoxicity and oxidative
stress are involved to various extents in the neurodegenerative process4-6. Neuroinflammation
is  an  important  mechanism  that  has  been  implicated  in  the  pathomechanism  of  many
neurodegenerative diseases7-9 and the normal aging process10. Activation of the microglia and
astrocytes has been detected in neurodegenerative disorders such as PD and HD, and this
process may even influence the release of Glu11-14. Mitochondrial disturbances result in an
energy deficit and the production of free radicals, which results in disruption of the membrane
potential  and  in  oxidative  stress.  Free  radicals  may  lead  to  protein  misfolding  or  lipid
peroxidation,  thereby damaging neuronal  cells.  As the brain  has  high oxygen and energy
demands,  it  is  especially  sensitive  to  energy  impairment  and  oxidative  damage.  A
mitochondrial dysfunction and oxidative damage have been described in AD, PD and ALS15-18.
Another key mechanism in the neurodegenerative process is Glu-mediated excitotoxicity. Glu,
the  main  excitatory  neurotransmitter  in  the  brain,  has  a  crucial  role  in  a  number  of
physiological functions, such as memory formation. However, the overactivation of excitatory
amino acid receptors may induce vicious downstream signalling pathways, finally leading to
neuronal  damage.  The  N-methyl-D-aspartate  (NMDA)  receptors  (NMDARs)  are  of
oustanding  importance  in  this  process.  Under  physiological  conditions,  activation  of  the
NMDARs  is  under  strong  control,  mainly  by  a  voltage-dependent  block  by  magnesium
(Mg2+).  Accordingly,  any  disruption  of  the  membrane  potential  as  a  consequence  of  a
mitochondrial impairment makes the neurons more vulnerable to excitotoxicity, for it releases
Mg2+ and allows excessive NMDA activation.
Recent findings strengthen the linkage between the endocannabinoid system (ECS) and the
kynurenine  pathway  (KP)19-20.  There  has  been  growing  interest  in  the  potential  of  the
therapeutic palette of cannabis and cannabinoid-based chemicals in neurological conditions in
recent decades. A role of the ECS has been implicated in motor control, cognition, mood,
feeding behaviour and pain21-24. Alterations in the ECS and/or the benefits of therapy have
been considered in PD25-28, HD29-31, migraine20, pain32-33 and multiple sclerosis (MS)34-35. The
preclinical and clinical research into the value of cannabinoids in movement disorders has
been reviewed by Kluger et al.36. There is an important risk of abuse in the case of cannabis-
based  drugs37,  but  the  enhanced  endogenous  brain  kynurenic  acid  (KYNA)  levels  could
probably mitigate this19.
The emerging evidence links chronic Toxoplasma gondii infections to disorders of the CNS.
This obligate intracellular protozoan parasite affects 30-50% of the total human population,
the frequency increasing with age38-39. Many publications have linked this infection with AD40,
PD41-42,  schizophrenia43,  migraine44-45,  headache46-48,  autism48,  autoimmune  diseases49,  MS50
and  other  diseases.  There  is  evidence  that  toxoplasmosis  has  an  impact  on  the  KP.  The
infection  causes  induction  of  the  expression  of  indoleamine  2,3-dioxigenase  (IDO),  the
increased formation of L-kynurenine (L-KYN), a decreased level of tryptophan (Trp), and an
increased level of dopamine, thereby stimulating tachyzoites proliferation51-52. Moreover,  T.
gondii infection  is  associated  with  persistent  (life-long)  neuroinflammation,  and  this
abnormality is associated with an increased production of Glu, mitochondrial damage, and
oxidative stress53. Investigations of the role of such infections in modulation of the KP in
different neurological disorders began with schizophrenia54.  This field promises interesting
findings in the future.
The role  of  the KP has  been extensively investigated in  immunoregulation,  in  which  the
enzyme IDO is of outstanding importance. IDO causes Trp depletion and is responsible for
the production of kynurenines, which occurs at the beginning of the enzymatic pathway. IDO
is expressed in various immune cells: monocytes, macrophages and microglia55-56. The activity
of IDO can be enhanced by interferons and lipopolysaccharides. Interferon-γ is considered to
be the main activator of IDO. The IDO activation leads to elevations in the levels of the
various  kynurenines,  among  them  KYNA.  IDO  counteracts  the  proliferation  of  reactive
lymphocytes, and can therefore be an important regulator of immune activation. This give rise
to a depletion of Trp, whereas quinolinic acid (QUIN) and 3-hydroxyanthranilic acid (3HAA)
result  in  the  selective  apoptosis  of  Th1  cells57-58.  This  function  is  considered  to  play  a
significant role as a negative feedback loop in the regulation of the immune response and may
contribute to the development of immune tolerance59-62. IDO-mediated T cell inhibition affects
primarily the Th1 cells however, through the activation of regulatory T cells56 this process
may influence Th2 cell activation as well.
2. The kynurenine pathway (KP)
2.1. The kynurenine metabolism
The scientific world has recently been demonstrating increasing interest  in the therapeutic
potential of the metabolites and enzymes of the main degradation pathway of the essential
amino acid Trp. Trp is transported across the blood-brain barrier (BBB) with the assistance of
the large neutral amino acid transporter63. In the human brain, 95% of the Trp is involved in
the  KP64 (the  remaining  5%  participates  in  the  serotonin  pathway  and  the  formation  of
proteins) (Figure 1). This metabolic route is responsible for the synthesis  of nicotinamide
adenine  dinucleotide  (NAD)  and  NAD  phosphate,  KYNA,  xanthurenic  acid  (XA)  and
picolinic acid (PIC). The central compound of the KP is L-KYN, formed from Trp, the rate-
limiting steps of its synthesis involving the enzymes IDO and  tryptophan 2,3-dioxygenase
(TDO). Most of the L-KYN (approximately 60%) is taken up from the blood65 with the aid of
the neutral amino acid carrier66, the remainder being generated locally in the CNS. After the
synthesis  of  L-KYN,  the  cascade  branches  into  three  routes.  The  first  possibility  is  the
synthesis  of  KYNA  from  L-KYN  through  irreversible  transamination  by  kynurenine
aminotransferases (KATs). The other main branch of the cascade begins with the formation of
the  neurotoxic  3-hydroxykynurenine  (3HK)  through  the  action  of  kynurenine-3-
monooxygenase (KMO), the third important enzyme in the KP. KMO is responsible for the
neurotoxic branch of the cascade,  the concentration of KYNA depending indirectly on its
activity. Kynureninase converts 3HK to 3HAA. In the third route, kynureninase converts L-
KYN to anthranilic acid, which further metabolize to 3HAA. Another neurotoxic metabolite
in the route is QUIN, which is synthesized from 3HAA by 3HAA oxygenase (3HAO). QUIN
is the precursor of NAD and NADP synthesis (Figure 1).
The infiltrating macrophages, activated microglia and neurons are capable of the complete
enzymatic cascade within the CNS, whereas the astrocytes and oligodendrocytes lack IDO
and KMO and are unable to produce the neurotoxic QUIN67. Most of the locally synthesized
neuroprotective KYNA and PIC68 is therefore generated in the astrocytes and neurons, while
QUIN is synthesized by the infiltrating macrophages and microglia69.
The term kynurenines is the overall name for the metabolites of this pathway; most of them
display neuroactive properties and three of them (KYNA, 3HK and QUIN) have key roles in
certain CNS disorders.
2.2. Neuroactive kynurenine metabolites and their impact on receptors in the CNS
KYNA: The most characteristic feature of this metabolite is the broad-spectrum, competitive
antagonism of all three ionotropic excitatory Glu receptors (the α-amino-3-hydroxy-5-methyl-
4-isoxazolepropionic acid receptor (AMPAR), the kainate receptor and the NMDAR) at high
micromolar  concentrations  (to  approximately  the  same degree)69.  It  is  most  active  at  the
NMDARs, after binding at the strychnine-insensitive glycine co-agonist site of the NMDAR
complex70. NMDAR-mediated excitotoxicity and free radical production are involved in the
pathology of many neurodegenerative disorders and the number of endogenous Glu receptor
antagonists  (similarly to the level of KYNA) is very low. Besides its main impact on the
NMDAR complex,  KYNA exerts  weak antagonistic impacts on the AMPARs and kainate
receptors  too.  However,  its  effect  on  the  AMPARs  depends  on  its  concentration:  at  low
concentrations  (nanomolar  to  micromolar)  it  behaves  as  a  facilitator,  whereas  at  high
concentrations (micromolar to millimolar) it behaves as an inhibitor71-72.
The α7 nicotinic acetylcholine receptors (nAChRs) are also important targets for KYNA, and
under  physiological  conditions  this  has  proved  to  be  extremely  determinative73.  Its  non-
competitive  antagonistic  impact  results  in  reduced  acetylcholine,  dopamine  and  Glu
signalling73.
The G protein-coupled receptor 35 (GPR35) and the aryl hydrocarbon receptor have recently
been identified  as  sites  of  action  of  KYNA, but  their  roles  in  connection  with  the  brain
function remain to be clarified. The action of KYNA on GPR35 may trigger the production of
inositol trisphosphate and cause Ca2+ mobilization. Nevertheless, its function is questionable,
because of the expression of GPR35 in the brain is low74.
Independently of its impact on the receptors, the in vitro and in vivo evidence confirms that
KYNA  has  antioxidant  and  free  radical  scavenger  properties75;  this  broadens  its
neuroprotective  features  and  focuses  attention  on  the  importance  of  KYNA-mediated
neuroprotection.
A recent study with the model organism Caenorhabditis elegans suggested a new feature of
KYNA: it is a nutritional cue that enables behavioural plasticity76.
QUIN: The neurotoxic properties of QUIN have led to its being widely used in animal models
of HD77-79. Its neurotoxic features80 are a consequence of its weak, but specific competitive
agonist action on the NMDAR subgroup including NR2A and NR2B55, 81. The NMDARs have
brain  region-specific  locations.  NMDARs  which  contain  NR2C  subunits  are  hindbrain-
specific, while NMDARs with NR2B subunits are found predominantly in the forebrain. This
results  in  regional  selectivity,  because  QUIN  binds  with  10-fold  lower  activity  to  the
hindbrain-specific NR2C subunits of the NMDARs as compared with the NR2B subunits82.
Apart from its activation on the NMDARs, it has a complex neurotoxic potential, including
the  enhancement  of  presynaptic  Glu  release83-84,  the  inhibition  of  astrocytic  Glu  uptake84,
depletion of the local antioxidant supply85, the generation of reactive oxygen intermediates86
and the peroxidation of lipid molecules81,  87, which depends strictly on the amount of Fe2+88.
Moreover, by influencing lipid peroxidation, Fe2+ directly regulates the binding of QUIN to
the NMDARs69, 89.
3HK:  The  toxic  features  of  this  metabolite  are  independent  of  the  NMDARs  and  are
connected only to  the  production of  free  radicals90.  Cultured  striatal  and cortical  neurons
treated with 3HK exhibited a reduced viability, irregular somata, and shrunken and reduced
neuritic  outgrowths91-92;  this  was  prevented  by the  antioxidant  catalase93.  In  contrast  with
neuronal cells92-93, cultured glioma cells did not display susceptibility to 3HK94-95. These data
indicate that glial cells may tolerate the presence and toxic effect of 3HK much more easily
than do neurons, in which 3HK is endogenously not present96. 3HK potentiates quinolinate,
but not NMDA toxicity in the rat striatum97. Intrastriatal co-administration of 3HK and QUIN
in subtoxic doses results  in neuronal death in the striatum, which indicates that 3HK has
neurodegenerative properties in the presence of QUIN97.
3HAA: Kynureninase  converts  3HK to  3HAA. This  metabolite  undergoes  auto-oxidation,
during  which  highly  reactive  hydrogen  peroxide  and  hydroxyl  radicals  are  formed98-99.
Superoxide  dismutase  1  enhances,  whereas  catalase  abolishes  these  reactions93,  99.  These
findings are evidence that the detrimental effect of 3HAA is mediated by reactive oxygen
species.
PIC:  PIC  is  one  of  the  metabolic  products  of  the  KP100.  Besides  KYNA,  PIC  displays
antagonism towards the toxic action of QUIN, though the exact mechanism is unknown101-103.
In vitro studies  suggest  that  it  has  an  immunomodulatory  character  besides  its  antiviral,
antimicrobial  and antitumour  effects,  but  the  experimentally  used  concentrations  in  these
studies were much higher than the reported endogenous concentration of PIC104. The large
discrepancy  between  the  endogenous  and  experimental  PIC  levels  means  that  these
observations may not be related to the natural physiological function of PIC.
XA: XA is formed from 3HK through the action of KATs.  XA is closely related to KYNA
structurally (the difference is merely a hydroxy group) (Figure 1). It  has been verified as a
ligand of the endogenous Group II (mGlu2 and mGlu3) metabotropic Glu receptors105. These
receptors  and the  metabolites  of  the  KP have  been implicated  in  the  pathophysiology of
schizophrenia. A recent study postulated that XA is probably the first potential endogenous
allosteric agonist for the mGlu receptors105. It has also been demonstrated to exert an anti-
inflammatory effect through a reduction of interferon-γ106.
3. The kynurenine pathway and the immune system in aging
Alterations in the levels of the KP enzymes and compounds have been observed not only in
neurological disorders107-109, but also in the aging process109-112. If the KP metabolism is
compared  in  older  individuals  and  in  young  adults,  upregulation  of  the  Trp-KYN
metabolism  may  be  noted  in  the  elderly113.  Moreover,  the  activity  of  IDO in
nonagenarians  is  markedly  increased  and  predicts  mortality114. Exploration  of  the
relationship between the KP and aging through the use of animal models is a unique and
useful  technique,  because  the  KP is  conserved  evolutionarily  in  insects,  rodents  and
humans.
Drosophila melanogaster is an ideal animal model of the aging process115,  because it  is a
cheap, fast-growing species in which many mutants have been described. In Drosophila,
the genes of the KP are responsible for the colour of the eyes. The end-product of the KP
pathway is the brown eye pigment116. The life spans of the mutant insects with vermilion
(TDO-deficient) or white eyes (ABC transport impaired) were longer than that of the
wild-type flies117. Moreover, a prolongation of the life span was exhibited in wild-stock
flies  treated  with  inhibitors  of  TDO  and  the  ABC  transporter,  treatments  which
presumably limit the conversion of Trp into L-KYN. Inhibition of the conversion of Trp
into L-KYN might therefore be a target for anti-aging intervention117.
Additionally,  the alterations in  the levels of the metabolites of the KP could underlie the
cognitive decline observed in  aging.  Investigations  of cardinal  Drosophila  mutants  (a
3HK excess) demonstrated a decline in learning and memory118. Vermilion Drosophila
mutants  (no  kynurenines)  displayed  a  gradual  decline  of  memory  performance  until
complete memory failure112.
An investigation of the KP metabolism in the brain, liver and kidney of aged female rats
revealed that  the Trp levels and TDO activity declined in all  tissues with advancing age,
whereas  the  IDO  activity  in  the  brain  increased,  while  that  in  the  liver  and  the  kidney
decreased110.  Trp  depletion  as  a  consequence  of  IDO  activation  may  contribute  to  the
development of the immunodeficiency observed in the elderly113. Braidy et al. measured not
only the enzyme activity, but also the metabolite levels. They found that the levels of KYN,
KYNA, QUIN and PIC in the brain tended to rise with advancing age, while those of KYN in
the liver and kidney exhibited a tendency to decrease110. The content of KYNA in the kidney
increased, but in the liver it did not change110. The concentrations of PIC and QUIN increased
significantly in the liver, but showed a tendency to decrease in the kidney110. The enhanced
brain IDO activity may be responsible for the observed age-dependent increase in brain KYN,
which is the central metabolite of the pathway. The elevated concentration of KYN therefore
adequately explains  the  observed  age-dependent  increases  in  the  KYNA, QUIN and PIC
concentrations.  The  elevated  levels  of  KYNA were  strengthened  by  the  results  of  two
experiments. An age-related increase was found in the level of KYNA in the human CSF119,
and elevated levels of KYNA and QUIN in the rat brain120-121.
Nevertheless, age-dependent alterations in the KP have been described not only in healthy
animal models, but also in specific disease models, e.g. in the YAC128 mouse model of HD109
and a C. elegans AD model111.
In summary, investigations of the KP are of considerable importance not only in diseases and
in disease models, but also in aging models. Exploration of the differences between normal
aging and neurodegenerative diseases may facilitate a better understanding of both processes.
The decline of the immune system with age can be detected in the increased susceptibility to
infections, in the modest immune response after vaccination, in the growing number of
cancer cases,  and in the increased number of autoimmune and other chronic diseases
characterized by a pro-inflammatory state among the elderly10,  122-125. Both the innate126
and the adaptive immune responses showed changes because of the aging process, but the
adaptive response seems to be more affected10. This topic is summarized in Table 1 and
has  been  well  reviewed  by  Castelo-Branco  and  Soveral10.  Inflamm-aging127,  the
characteristic  chronic  low-grade  inflammatory state  observed  in  aged  individuals  has
been implicated in the pathogenesis of many age-related diseases, such as AD128-129. This
process is characterized by increased levels of proinflammatory markers and cytokines
and it should be taken into account when we speak about CNS disorders, which appear
mostly in elderly populations. 
4. Alterations in the kynurenine pathway in some disorders of the CNS
The social significance of these disorders is enormous, even if only the worktime lost because
of  migraine  or  the  costs  of  drugs  and  hospitalization  are  considered.  Unfortunately,  the
therapeutic  options  in  a  number  of  these  diseases  are  limited.  The  pathomechanisms  of
neurological  disorders  exhibit  common  features.  The  characteristic  changes  are  a
mitochondrial  dysfunction,  the  accumulation  of  free  radicals,  the  starting  of
neuroinflammatory processes and excitotoxic and oxidative damage of the cells, ultimately
leading to neuronal cell death. Since the destruction of nerve cells can result in a permanent
loss of function, there is a need for the prevention of cellular damage, i.e. neuroprotection55.
4.1. Parkinson’s disease
PD  is  a  chronic  progressive  neurodegenerative  disease  with  characteristic  pathological
hallmarks,  including selective degeneration of the dopaminergic  neurons in the substantia
nigra pars compacta (SNPC) and the appearance of intracytoplasmic alpha synuclein protein
inclusions,  Lewy  bodies130.  The  accumulation  of  free  radicals,  malfunctioning  of  the
mitochondria,  abnormal  protein  aggregations,  neuroinflammatory  processes  and
overproduction of the excitatory neurotransmitter Glu have critical roles in the pathogenesis
of the disease. The most widely utilized treatment is with L-Dopa and a dopaminergic agonist,
but these only relieve the symptoms at most; moreover, their long-term usage may give rise to
serious side-effects (dyskinesia or motor fluctuations)131.
Increasing evidence has emerged of an association between PD and alterations in  the KP
(Table 3). Lower concentrations of KYN and KYNA were measured in the frontal cortex,
putamen  and  SNPC  of  PD  patients  as  compared  with  controls132.  Additionally,  the
concentration of 3HK was elevated in the putamen and SNPC in the PD group132.
There  are  alterations  in  the  KP in  the  two  widely  used  animal  models  of  PD133-135.  The
expression of KAT I in the substantia nigra of mice was decreased after 1-methyl-4-phenyl-
1,2,3,6-tetrahydropyridine  treatment133.  Moreover,  1-methyl-4-phenylpyridinium  and  3-
nitropropionic acid diminished the cortical synthesis of KYNA in rats via interference with
the KATs135. Alterations in the KP in the periphery have also been demonstrated in PD. The
increased activity of KAT II in correlation with the elevated KYNA level in the red blood
cells may relate to a possible protective process136. The importance of the KP was supported
by experiments in which the inhibition of KMO increased the KYNA level, thereby not only
preventing neurotoxic damage of the striatal dopaminergic neurons, but also alleviating the
dyskinesia caused by dopamine replacement137-138. However, despite increasing evidence of
the linkage of KP and PD, genetic evidence is not yet available130. Both  in vitro139 and  in
vivo137, 140-141 experiments indicate therapeutic possibilities through elevated levels of KYNA.
4.2. Huntington’s disease
HD is an autosomal dominantly inherited neurodegenerative disease caused by trinucleotide
expansion (CAG-glutamine) within exon 1 of the huntingtin protein (htt-located 4p16.3). This
leads to neuronal cell death in the brain, and especially in the striatum and cortex, which
causes  motor,  cognitive  and  psychiatric  symptoms.  The  age  at  disease  onset  correlates
inversely with the length of the CAG expansion. Genetic modifiers and the environment play
critical  roles  in  patients  who  have  36-39  repeats142.  Especially  in  these  individuals,  but
certainly in those who exhibit symptoms (>40 repeats), manipulation of the KP may be a
beneficial tool.
In the early phase of the disease, increased QUIN and 3HK and moderately increased KYNA
concentrations have been measured in the striatum, associated with decreased KYNA/QUIN
and KYNA/3HK ratios55, 143 (Table 3). These results were strengthened by a full-length mutant
huntingtin mouse model144. In the late stages, the KYNA levels are decreased in the cortex,
striatum and CSF145-146, while that of 3HK is increased in the brain147. Decreased KAT activity
has been demonstrated in the striatum145,  148, and elevated 3HAO activity in the brain149. An
abnormal Trp metabolism has been revealed in the periphery (plasma)150. Increased KMO and
decreased kynureninase activity have been observed in transgenic R6/2 mice151. Moreover, the
3HK levels were significantly and selectively elevated in the striatum, cortex and cerebellum
in this model, starting at 4 weeks of age152. The levels of both 3HK and QUIN were enhanced
in  the  striatum  and  cortex  of  the  full-length  HD  models,  YAC128  and  Hdh(Q92)  and
Hdh(Q111)152. Intrastriatal administration of QUIN has been widely used as an animal model
of HD, leading to  an elevation of extracellular glutamate.  Interestingly,  this  effect can be
prevented by cannabinoid receptor agonists31.
Genetic and pharmacological inhibition of KMO and genetic inhibition of TDO increase the
level  of  the  neuroprotective  KYNA  relative  to  the  neurotoxic  3HK  and  ameliorates
neurodegeneration in a D. melanogaster HD model153.
Elevated  levels  of  KYNA (or  its  analogues)  or  inhibition  of  KMO  and  TDO  provide
therapeutic possibilities for neuroprotection in HD153-155.
4.3. Alzheimer’s disease
AD is  the  most  prevalent  neurodegenerative  disorder,  accounting for  60-70% of  cases  of
dementia. The  pathological  hallmarks  of  the  disease  are  the  amyloid  plaques and
neurofibrillary tangles, which are clearly visible by microscopy in the brains of those afflicted
by AD156. Excessive activation of NMDA receptor signalling is believed to contribute to the
neuronal damage in AD157, which is confirmed by neuroanatomical data, because the loss of
neocortical  neurons  is  restricted  to  the  Glu-ergic  neurons  in  layers  III  and IV158 and  the
cortical  and  hippocampal  neurons  innervated  by  L-Glu159.  This  is  supported  not  only  by
neuroanatomical  observations,  but  also  by the  therapeutic  effect  of  the  low-affinity  non-
competitive NMDA receptor antagonist, memantine.
The relationship between AD and the KP is  also indicated by other observed alterations55
(Table 3).  The KP is up-regulated in the AD brain; the regulatory enzyme of the pathway,
IDO, is abundant in AD as compared with controls, leading to increase in the excitotoxin
QUIN108.  Moreover,  QUIN  is  co-localized  in  the  cortex  with  phosphorylated  tau160 and
induces tau phosphorylation in human primary neurons160. Alterations are also observed in the
periphery;  the  serum level  of  3HK was  markedly increased  in  AD patients,  but  the  Trp,
KYNA, PIC and QUIN concentrations were similar to those in the controls161. The KYNA
concentration  was significantly decreased both in the plasma and in the red blood cells, but
the levels of KYN and the activities of KAT I and KAT II remained unchanged162. In a mouse
model of the disease, the IDO inhibitor coptisine ameliorated the cognitive impairment163.
4.4. Multiple sclerosis
MS, the most common chronic autoimmune/neurodegenerative demyelinating disorder of the
CNS acording to Lucchinetti164, emerges mostly in young adults and affects 2.5 million people
worldwide. In a recent study, the standardized prevalence was found to be 83.7/100,000 and
the female:male ratio in the MS population in Csongrád County, Hungary was 3.08165. The
clear  role  of  a  genetic  predisposition  has  been  suggested,  together  with  unidentified
environmental factors and autoimmune inflammatory mechanisms. The lifetime risk has been
reported  to  be  1  in  400166,  which  makes  MS  potentially  the  most  common  cause  of
neurological disability in young adults.
The KP plays a pivotal role in regulating the balance between activation and inhibition of the
immune system through the immunomodulatory effect of IDO56.  The linkage between the
kynurenine  system  and  immunoregulation  has  been  reviewed55-56.  IDO  has
immunosuppressive action, and IDO-KP can serve as a negative feedback loop for Th1 cells56,
which can be important in MS therapy.
It may be presumed that not merely IDO plays a crucial role in MS, as QUIN and 3HK proved
to  be  elevated  in  the  more  caudal  regions  of  the  spinal  cords  of  the  animals  in
experimental autoimmune encephalitis (EAE), an animal model of MS167-168 (Table 3).
Furthermore, the linkage of KP and MS and the therapeutic benefit of modulation of the
cascade  are  strengthened  by  another  EAE  model  study169-170.  In  that  work,  the  KP
metabolite  cinnabarinic  acid  (an  endogenous  agonist  of  the  type-4  metabotropic  Glu
receptor) suppressed EAE in mice169-170. Moreover, recent results indicated QUIN-induced
oligodendrogliotoxicity in two cell  lines171,  which could be attenuated by specific KP
enzyme inhibitors and anti-QUIN monoclonal antibodies. This could be very important in
MS, where the pathological hallmark is irreversible demyelination.
The  levels  of  KYNA  in  the  CSF  of  relapsing-remitting  MS  (RRMS)  patients  were
significantly  lower  during  remission172.  By  contrast,  the  KYNA levels  in  the  CSF  were
elevated during acute relapse173. A recent study not only investigated the KP metabolite levels
from the CSF, but was also the first comprehensive analysis of CSF kynurenine metabolites in
MS patients in different disease stages in relation to neurocognitive symptoms. At the group
level, MS patients did not show any difference in the absolute levels of the KP metabolites
(Trp, L-KYN, KYNA and QUIN) as compared with the control group, but the stratification of
the data according to the disease course revealed that both absolute the QUIN levels and the
QUIN/L-KYN ratio were increased in RRMS patients in relapse, the secondary progressive
MS patients showed a tendency to lower Trp and KYNA concentrations, and the primary
progressive cohort displayed increased levels of all metabolites (similarly to the inflammatory
neurological disease controls)129,  174.  The  depressed patients demonstrated higher KYNA/Trp
and L-KYN/Trp ratios (mainly due to low Trp levels)129, 174. There was no linkage between the
pattern of KP metabolites  in  RRMS patients and the neurocognitive symptoms129,  174.  The
study  concluded  that  the  clinical  disease  activity  and  differences  in  disease  courses  are
correlated with the changes in KP metabolites129, 174. In the periphery, elevated levels of KYNA
and KAT I and KAT II activities have been reported in the plasma and erythrocytes175. These
changes  may indicate  a compensatory protective mechanism against  excitatory neurotoxic
effects.
It is questionable whether activation of the KP in MS is beneficial or detrimental. It may be
beneficial in the early stages, because IDO activation can downregulate T cell proliferation. In
contrast, prolonged activation of the KP may lead to chronically elevated levels of QUIN and
other  neurotoxins  produced  by perivascular  macrophages,  thereby  contributing  to  further
neurological deficits176. In an animal model of MS, the activation of IDO ameliorated177-178,
while the inhibition of IDO exacerbated EAE176,  179, and anti-inflammatory metabolites of the
KP ameliorated EAE180. The therapeutic aspects of the KP in MS and the role of the KP in the
dialogue between the immune system and the CNS were well reviewed recently.
4.5. Amyotrophic lateral sclerosis
ALS  is  a  rapidly  progressive  and  fatal  neurodegenerative  disease  with  characteristic
pathological features: degeneration of the upper (cortical) and lower (spinal and pontobulbar)
motor neurons. Despite the fact that it is the most common motor neuron disease, ALS is rare.
Its mean incidence in Europe is 2.8/100,000, while its mean prevalence is 5.40/100,000181.
Only 5-10% of the cases are classified as familial, which mainly inherited in an autosomal
dominant manner182-183, the remaining 90% being sporadic184.
Glu excitotoxicity, damage by free radicals, a mitochondrial dysfunction, intracellular protein
aggregation, excessive  poly (ADP-ribose) polymerase activation, autoimmune inflammatory
processes and the enhanced accumulation of intracellular Ca2+ are involved in the aetiology of
the disease183.
Currently only one  effective mode of  therapy exists (Riluzole, an anti-Glu agent similar to
KYNA), which slowed the progression and possibly improved the survival in patients with
bulbar onset in a double-blind placebo-controlled clinical trial183, 185.
The role of Glu in ALS is not only supported by this therapeutic possibility; loss of a key Glu
transporter (the Glu transporter-1 isoform responsible for keeping the extracellular Glu levels
below neurotoxic), and increased extracellular Glu levels have also been described in both the
sporadic and the familial form of ALS186. 
The oxidative degradation of Trp early in the pathway results in covalent cross-linking and the
accumulation  of  human  superoxide  dismutase  1,  one  of  the  two  major  genetic
contributors to ALS known to date187 and therefore widely used in an animal model of
ALS.
The linkage of the KP and ALS is additionally indicated by the alterations in the KP in ALS
(Table 3). Significantly increased levels of Trp, KYN and QUIN in the CSF and serum,
and a decreased serum level of PIC have been measured in ALS samples, with enhanced
microglial  and neuronal IDO expression in the motor  cortex and the spinal  cord and
elevated IDO activity in the CSF188. High KYNA levels were measured in the CSF in
patients with a severe clinical status or with bulbar onset,  whereas the serum KYNA
levels were decreased in cases with a severe clinical status189. These changes are probably
a part of the neuroprotective compensation.  In vitro experiments with the NSC-34 cell
line showed that KYNA may have anti-apoptotic features190-191. An animal model of the
disease revealed  changes  in  zinc-binding capacity192-193,  and PIC could therefore be  a
neuroprotectant  in  ALS because of  its  zinc chelator  property.  These findings  provide
strong evidence of the involvement of the KP in ALS, therefore possibly opening the way
for new therapeutic opportunities in this fatal disease.
4.6. Migraine
Migraine,  the most  common type  of  primary headache,  is  a  multifactorial  recurrent  brain
disorder194. Its cumulative incidence has been reported to be 43% in women and 18% in
men195. In 75% of the cases, the age at onset is less than 35 years195. Because of its high
frequency, its economic importance should not be underestimated, in view of the costs of
treatment, the loss of worktime and the decrease in productivity. The electrophysiological
hallmark  of  the  disease  is  cortical  spreading  depression  (CSD),  an  excitatory slowly
progressing  wave  of  depolarization  accompanied  by  a  long-lasting  suppression  of
neuronal activity and excitability in the cortex of the brain196. CSD is assumed to be the
neurological basis of the aura phenomenon197, which affects one-third of migrainers198. In
the  pathomechanism  of  migraine,  genetic  factors199,  peripheral  sensitization  of  the
trigemino-vascular  system  (caused  by  the  changed  cerebral  blood  flow  and  sterile
neurogenic inflammation)200-201, central sensitization of the caudal trigeminal nucleus202,
the activation of specific brain stem nuclei, called migraine generators (the dorsal raphe
nucleus,  the  nucleus  raphe  magnus,  the  locus  coeruleus  and  the  periaqueductal  grey
matter)203-205 and, not least, the development of CSD206 are assumed. The common feature
of these five processes is the role of Glu in each207 and the importance of Glu in the
pathomechanism is  also  indicated  by  the  elevated  Glu  levels  in  the  CSF during  the
attacks208, and  in  the  plasma  (without  aura)  and  in  the  platelets  (with  aura)  in  the
headache-free periods209, which may reflect persistent hyperexcitability208. Because of this
common point, the therapeutic possibilities draw attention to the NMDA antagonist of the
KP, KYNA. Elevated levels of KYNA or its analogues significantly attenuate the central
sensitization  of  the  caudal  trigeminal  nucleus210-211 and  alleviate  the  activation  of  the
migraine generators212 and primary and secondary trigeminal nociceptive neurons213-214;
moreover, KYNA inhibits CSD both in the cerebellum and in the neocortex215. L-KYN or
a synthetic KYNA analogue was also able to decrease nitroglycerine-induced calcitonin-
gene  related  peptide  (CGRP)  expression211.  CGRP  is  one  of  the  most  investigated
neuropeptides  in  research,  especially  because  CGRP  antagonists  and  monoclonal
antibodies are of promise for the therapy of migraine216-219. Although increased KYNA
levels  have  been  found  in  the  rat  brain  after  triggered  CSD,  this  is  presumably  an
adaptive response for neuroprotection55,  207. KYNA additionaly alleviates the nociception
caused by formalin and capsaicin in animal models220-221. The systemic administration of
KYN attenuates the frequency of CSD in female rats, whereas in male rats this effect was
observed only when probenecid was co-administered222. However, the administration of
KYN  with  probenecid  not  only  influences  CSD,  but  also  mitigates  the  central
sensitization of the caudal  trigeminal  nucleus210,  223.  After  electrical  stimulation of  the
trigeminal ganglia (migraine model), decreased KAT immunoreactivity was detected in
the dural  macrophages,  Schwann cells  and mast  cells55,  224,  which  leads  to  a  reduced
production of KYNA. These results indicate that kynurenine metabolites can influence
the brainstem structures involved in the pathogenesis of migraine, and KYNA and its
analogues may serve as a novel and useful therapeutic approach.
4.7. Schizophrenia
Schizophrenia  is  a  disorder  characterized  by  psychiatric  symptoms  and  a  cognitive
dysfunction. Its pathology involves biochemical alterations in Glu neurotransmission (hypo-
Glu-ergic hypothesis), which can cause secondarily altered dopamine homeostasis225. This Glu
deficiency theory has been strengthened by genetic studies226.
Investigations of the KP in schizophrenia revealed increased KYNA levels in the CSF and in
post-mortem tissues225, 227-229, whereas the level was lower in the blood of the patients230 and in
an animal model231 (Table 3). The KYNA level was elevated in the prefrontal cortex225,  227,
where a reduced metabolic function has been at the focus of interest in schizophrenia studies.
Indeed, increased concentrations of this NMDAR antagonist can cause a hypo-Glu-ergic state
in  the  brain232-233.  The  increased  KYNA levels  may  be  caused  by  reduced  levels  of  the
enzymes responsible for the synthesis in the other branches of the pathway. The activities of
the enzymes, and the protein and mRNA levels of 3HAO and KMO proved to be reduced in
the prefrontal cortex region in post-mortem samples, while those of IDO, KAT and quinolinic
acid phosphoribosyltransferase were normal234-235. The 1q42-q44 chromosome region, where
KMO is located,  has been implicated in the disease aetiology236-237.  Another genetic study
supported  the  role  of  KMO  in  schizophrenia,  in  which  the  rs1053230  single  nucleotide
polymorphism  was  found  to  be  strongly  associated  with  increased  CSF  KYNA
concentrations233 in both controls and patients, but another, larger study failed to establish a
significant association of KMO and schizophrenia238. This contradiction could be due to the
different populations. Aoyama et al.  used only the clinical diagnosis and no other clinical
parameters,  and  they  collected  Japanese  samples  from  different  geographical  regions.
Interleukin-1B  and  IDO  single  nucleotide  polymorphisms  were  studied  together  and  a
combination  of  alleles  was associated  with schizophrenia239.  These  results  may indicate  a
slight genetic association and support the role of the KP in this disease.
In animal models of schizophrenia, elevated KYNA levels may be associated with cognitive
deficits69, 225. The decrease of the extracellular Glu concentrations by KYNA was accompanied
by the  deteriorating  performance  of  mice  and  rats  in  different  cognitive  tests,  while  the
inhibition of KAT (which decreases the KYNA level) secondarily increases the release of Glu
and improves the skills of the animals225.
In summary, investigation of the KP is important in schizophrenia, and might be important in
the future in other psychiatric diseases too (bipolar disorder and autism)240-242. In contrast with
the diseases described above, the decreased Glu and increased KYNA levels may contribute
to the development of schizophrenia.
3. Possibilities for neuroprotection by modulating the kynurenine pathway
As discussed above, KYNA is a neuroprotective agent because of its broad-spectrum non-
selective anti-Glu properties.  Its  neuroprotective action has been demonstrated against the
neurotoxicity induced by kainate, ibotenate, QUIN or NMDA243. This metabolite of the KP is
therefore of therapeutic potential, but unfortunately it has only a very limited ability to cross
the BBB. For therapeutic exploitation, there are four main possibilities. One option is to use
precursors  of  KYNA, L-KYN or  its  halogenated  derivatives,  which  cross  the  BBB more
readily (prodrug concept). A second possibility is to synthetize KYNA analogues which pass
through the BBB more easily,  but have at least the same neuroprotective effect as that of
KYNA. A third option is to shift the KP towards the production of KYNA through the use of
enzyme inhibitors. A fourth possibility is to make use of the innovations of nanotechnology,
“packing the KYNA”, which results in easier passage of the compound through the BBB
(Figure 2).
4.8.  Prodrug concept
Preclinical  studies  have  verified  the  efficacy of  pretreatment  with  the  neuroprotective  L-
KYN244-245, which proved more effective when co-administered with probenecid in different
disease  models:  epilepsy246,  migraine  (L-KYN combined  with  probenecid  and  a  novel
synthetic KYNA derivative attenuated nitroglycerine-induced neuronal  nitric oxide synthase
in the rat caudal trigeminal nucleus210-211), PD140 and AD247. Systemic L-KYN and probenecid
administration  displayed  a  protective  effect  against  the  behavioural  and  morphological
alterations induced by toxic soluble amyloid beta(25-35) in the rat hippocampus248. However,
the results of post-treatment were contradictory, as it was reported to be much less effective245,
possibly harmful249 or possibly beneficial in animal ischaemia models250.
Co-administration of L-KYN with probenecid may theoretically result  in an elevation not
only  of  KYNA,  but  also  of  neurotoxic  kynurenines.  However,  the  promising  results  in
preclinical studies suggest that probenecid may predominantly lead to the elevation of the
neuroprotective  KYNA251.  On  the  other  hand,  probenecid  may also  participate  in  several
interactions  with  medications.  Further  research  is  therefore  designed  to  overcome  the
limitations of this prodrug concept and influence the KP in a more specific way.
Halogenated derivatives of L-KYN (4-chlorokynurenine (AV-101) or 4,6-dichlorokynurenine)
are  transformed  into  7-chlorokynurenic  acid  and  5,7-dichlorokynurenic  acid,  these
compounds having increased affinity for the glycine co-agonist site of the NMDAR252. AV-
101 is the most advanced L-KYN prodrug candidate for use as a neuroprotective agent55.
Moreover, it may have therapeutic potential in epilepsy, HD and PD55.
These results lend support to the existence of a critical link between the Trp metabolism in the
blood  and  neurodegeneration,  and  provide  a  foundation  for  the  treatment  of
neurodegenerative diseases.
4.9.  The metabolic shift concept
Another  pharmacological  approach  is  the  use  of  KP  enzyme  inhibitors  (Table  2).
Neuroprotection can be achieved by making a metabolic shift towards the neuroprotective
KYNA instead of the neurotoxic 3HK, 3HAA and QUIN55.
During  the  past  two decades,  many novel  enzyme inhibitors  have  been developed which
target KMO, kynureninase and 3HAO (Table 2) to attain this metabolic shift55.
The early attempts were made with compounds that proved to be non-selective inhibitors, e.g.
nicotinylalanine, but the later work was successful and combined therapy with prodrugs or
analogues is now available55.
Orally administered 3,4-dimethoxy-N-[4-(3-nitrophenyl)thiazol-2-yl]benzenesulfonamide was
found to be a high-affinity inhibitor of KMO in vitro in the gerbil brain253, but unfortunately it
has  rapid  clearance.  JM6  (3,4-dimethoxy-N-(4-(3-nitrophenyl)-5-(piperidin-1-
ylmethyl)thiazol-2-yl)benzenesulfonamide),  a  novel,  peripherally  active  KMO  inhibitor
prodrug, overcomes the problem of the rapid clearance and elevates the level of L-KYN in the
blood, resulting in neuroprotection in animal models of HD and PD254.
4.10.  The kynurenic acid analogue concept
The  synthesis  of  novel  KYNA derivatives  is  a  promising  therapeutic  approach  for  the
development of new neuroprotective compounds154,  255-256. The most common analogues are
halogenated  (7-chlorokynurenic  acid  and  5,7-dichlorokynurenic  acid),  thio-substituted
(thiokynurenates) or sugar derivatives (D-galactose-7-chlorokynurenic acid or glucosamine-
kynurenic  acid).  The  various  chemical  changes  during  the  synthesis  result  in  different
beneficial  features.  The  therapeutic  advantages  of  the  halogenated  and  thio-substituted
derivatives  are  elevated  affinity  and  selectivity  for  the  glycine  co-agonist  site  of  the
NMDARs, while the sugar components contribute to more facile passage through the BBB.
Recent novel synthetic derivatives include KYNA amides, which are presumed to exert their
effects preferably on NR2B subunit-containing NMDARs257.
During the past decade, we have synthetized and tested a number of KYNA analogues256, the
most  promising  one  being  (N-(2-N,N-dimethylaminoethyl)-4-oxo-1H-quinoline-2-
carboxamide hydrochloride258, which is of proved neuroprotective value in animal models of
cerebellar ischaemia259 and HD154.
4.11. Possibilities in nanotechnology
The development of nanotechnology-based carrier systems offers novel promising technology
for drug delivery into the brain260. Through the use of these carriers, therapeutic drug levels
may be achieved in the brain, even for drugs which would otherwise not reach the CNS. This
approach  has  been  investigated  to  facilitate  KYNA delivery  into  the  brain  by  preparing
micelles as nanoscale containers261:  non-ionic surfactants were used to deliver KYNA, the
central effects of which were proved in  in vivo studies after peripheral administration too.
However, further research is needed to develop biodegradable, biocompatible and non-toxic
nanocarrier  systems  capable  of  promoting  drug  delivery  into  the  brain  without  causing
permanent damage to the BBB integrity.
5. Concluding remarks
A growing  body  of  evidence  implicates  alterations  in  the  KP  in  aging  and  in  many
neurocognitive and neurodegenerative disorders (PD, HD, AD, MS, ALS, schizophrenia and
migraine).  NMDAR-mediated  excitotoxicity,  which  causes  neurodegeneration,  occupies  a
central role in the pathophysiology of these diseases. Consequently, a pharmacological shift
towards elevated concentrations of the neuroprotective KYNA may well  be of therapeutic
potential.  There  are  currently  four  concepts  through  which  to  achieve  elevated  levels  of
KYNA: the use of more penetrable precursors; the synthesis of KYNA analogues, which can
cross the BBB more easily; the utilization of specific enzyme inhibitors to shift the metabolic
pathway  towards  the  formation  of  KYNA;  and  the  application  of  nanotechnology  and
“covered” KYNA.
This review has focused not only on the the linkage between neurological diseases and the
KP, but also on the normal aging process. Continued exploration of the differences between
normal aging and late-onset neurodegenerative disorders may promote a better understanding
of both processes.
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Tables
Table 1. Changes in the adaptive and innate immune system with age
Type of changes Innate immune system Adaptive immune system
Increase Impairment of anatomical 
barriers:
Numbers of less functional 
NK cells
Apoptosis resistance of 
memory B cells
Delayed antibody response to
new antigens:
Antigen-independent 
activation and proliferation 
of naive T cells
Apoptosis resistance of 
memory T cells
Decrease Impairment of anatomical 
barriers:
Number of Langerhans cells
Pathogen recognition by 
dendritic cells
Neutrophil survival in 
response to stimuli
Neutrophil phagocytic 
function and respiratory burst
generation
Cytokine production by 
macrophages
T cell activation by 
macrophages
Lymphoid progenitor 
production
Number of B cells, especially
naive cells
Antibody production, with 
lower affinities and 
decreased opsonizing 
abilities
Delayed antibody response to
new antigens:
Number of T cells, especially
naive and CD8+ cells
CD28+ T cells as a result of 
accumulation of mature cells
Acquisition of NK cell 
markers by T cells:
Cytotoxic capability of CD8+
cells
Source of the data: Castelo-Branco, C.; Soveral, I., The immune system and aging: a review.
Gynecol Endocrinol 2014, 30 (1), 16-22.
Table 2. Enzyme inhibitors of the KP
Inhibitors of the KP
IDO inhibitors Selective KAT II inhibitors
4‐Amino‐1,2,5‐oxadiazole-3‐
carboximidamide
S-Adenosylhomocysteine
AC 12308 (S)-(4)-(Ethylsulfonyl)benzoylalanine
BTB 05536 4-Carboxy-3-hydroxyphenylglycine
Keto-indole derivatives L-Cysteine sulfinic acid
2-Mercaptobenzothiazole L-Aspartate
S-Benzylisothiourea 
derivatives
Quisqualic acid
Annulin A, B and C KMO inhibitors
KM 00593 4-Aryl-2-hydroxy-4-oxobut-2-enoic acid derivatives
Garveatin A, C and E (m-Nitrobenzoyl)alanine
NSC 401366 FCE‐28833A (also known as PNU 156561)
4-Phenylimidazole 
derivatives
Nicotinylalanine
Berberin UPF 648
Benzylthiol derivatives S(+)-(m-Nitrobenzoyl)alanine
β-Carboline derivatives Ro 61-8048 and related benzenesulfonamides
Exiguamine A, B Kynureninase inhibitors
6-Chloro-DL-tryptophan Bicyclic L‐kynurenine analogues
Hydroxyamidine derivatives S-Aryl-l‐cysteine S,S-dioxides
1-Methyl-DL-tryptophan O-Methoxybenzoylalanine
1-Methyl-L-tryptophan O-Aminobenzaldehyde
N-Methyl-L-tryptophan 3-Hydroxyhippuric acid
Methylthiohydantoin-DL-
tryptophan
(m-Nitrobenzoyl)alanine
D,L-Homocysteine Nicotinylalanine
CAY10581 and other novel 
naphthoquinones
(4R)- and (4S)-dihydro-l‐kynurenine derivatives
D,L-Indole-3-lactic acid Desaminokynurenine derivatives
L-Glutamine 3‐HAO inhibitor
3-Indolepropionic acid 4-Halo-3-hydroxyanthranilic acid derivatives
L-Phenylalanine 4,5- and 4,6‐dihalo-3‐hydroxyanthranilic acid 
derivatives
L-Tryptophan
Source: A modified table, extended version can be found in Vecsei et al.: Kynurenines in the
CNS: recent advances and new questions. Nat Rev Drug Discov55
Table 3. Alterations in the KP in some neurological disorders
Diseases Alterations Location Refs
Parkinson’s 
disease
Homo sapiens ↓L-KYN, KYNA frontal cortex, 
putamen, SNPC
132
Homo sapiens ↑3HK putamen, SNPC 132
Homo sapiens ↑KAT II activity, 
KYNA
red blood cells 136
Homo sapiens ↓KAT I, KAT II 
activity, KYNA 
(tendency)
plasma 136
Mus musculus ↓KAT I decreased 
expression
substantia nigra 133
Rattus 
norvegicus
↓KYNA cortex 135
Huntington’s 
disease
Homo sapiens 
early phase of 
the disease
↑QUIN, 3HK and 
poorly elevated 
KYNA
striatum 55, 143
Homo sapiens 
early phase of 
the disease
↓KYNA/QUIN, 
KYNA/3HK
striatum 55, 143
Homo sapiens 
late phase of 
the disease
↓KYNA cortex, striatum, CSF 145-146
Homo sapiens ↑3HK post-mortem brain 
tissue
147
Homo sapiens 
early phase of 
the disease, 
Mus musculus
↑3HK, KYNA, 
3HK/KYNA
neostriatum 144
Homo sapiens ↓KAT activity striatum 145, 148
Homo sapiens ↑3HAO activity brain, striatum 149
Homo sapiens ↑L-KYN/Trp, IDO
activity, L-KYN, 
↓KAT activity, 
3HK, 3HAA
blood 150
Mus musculus
(R6/2 mice)
↑KMO activity, 
3HK, 
↓kynureninase
cortex, striatum, 
cerebellum
151
Mus musculus 
(R6/2 mice)
↑3HK striatum, cortex, 
cerebellum
152
Mus musculus 
(YAC128, 
Hdh(Q92), 
Hdh(Q111))
↑3HK, QUIN striatum, cortex 152
Alzheimer 
disease
Homo sapiens ↑QUIN, IDO 
activity
hippocampus 108
Homo sapiens ↑3HK serum 161
Homo sapiens ↓KYNA blood (plasma, red 
blood cells)
162
Multiple 
sclerosis
Homo sapiens 
remission
↓KYNA CSF 172
Homo sapiens 
acute relapse
↑KYNA CSF 173
Homo sapiens 
acute relapse, 
in relapsing-
remitting MS
↑absolute QUIN, 
QUIN/L-KYN 
ratio 
CSF 129
Homo sapiens 
secondary 
progressive MS
trend to lower Trp 
and KYNA
CSF 129
Homo sapiens 
primary 
progressive MS
↑Trp, L-KYN, 
KYNA or QUIN
CSF 129
Homo sapiens 
acute relapse
↑KAT I and KAT 
II activities 
RBC 175
Homo sapiens 
acute relapse
↑KYNA plasma, tendency in 
the RBC
175
Rattus 
norvegicus 
(EAE model)
↑QUIN more caudal regions of
the spinal cord
167
Rattus 
norvegicus 
(EAE model)
↑KMO activity, 
3HK, QUIN
spinal cord 168
Amyotrophic 
lateral sclerosis
Homo sapiens ↑Trp, L-KYN, 
QUIN
CSF, serum 188
Homo sapiens ↓PIC serum 188
Homo sapiens ↑IDO expression motor cortex, spinal 
cord
188
Homo sapiens ↑IDO activity CSF 188
Homo sapiens 
severe clinical 
status/bulbar 
onset
↑KYNA CSF 189
Homo sapiens 
severe clinical 
status
↓KYNA serum 189
Migraine
Rattus 
norvegicus 
after triggered 
CSD
↑KYNA brain 55, 207
Rattus 
norvegicus 
after triggered 
CSD
↓KAT 
immunoreactivity
dural macrophages, 
Schwann cells, mast 
cells
55, 224
Schizophrenia
Homo sapiens ↑KYNA CSF, post-mortem 
tissues
225, 227-229
Homo sapiens ↑KYNA prefrontal cortex 225, 227
Homo sapiens ↓KYNA, 
KYNA/KYN, 
KYNA/3HK, 
↑3HK
blood (plasma) 230
Homo sapiens ↓3HAO and KMO
activity, mRNA, 
protein, ↑KYNA
post-mortem prefrontal
cortex
225, 235
Homo sapiens ↓KMO activity, 
mRNA levels, 
protein
post-mortem frontal 
eye field
225, 234
Rattus 
norvegicus
↓KYNA, 
neuroprotective 
ratio
social isolation rearing
animal model
231
Rattus 
norvegicus
↑Trp, L-KYN, 
anthranilic acid, 
3HAA, QUIN
social isolation rearing
animal model
231  _
Figures
Figure 1. Kynurenine pathway
Figure footnotes: 1: Tryptophan dioxygenase (TDO) and indoleamine 2,3-dioxygenase (IDO).
These enzymes represent the rate-limiting step of the synthesis of the central metabolite, L-
kynurenine (KYN). The expressions of the two enzymes differ: IDO is mainly expressed in
the CNS, and TDO primarily in the liver. 2: Formamidase. 3: Kynurenine aminotransferases
(KATs). Four types of KATs (KAT I-IV) have so far been identified. In humans the most
important are KAT I and KAT II. 4: Kynurenine-3-monooxygenase (KMO). Inhibition of this
enzyme results in a metabolic shift towards the neuroprotective kynurenic acid (KYNA). 5:
Kynureninase.  6:  Non-specific  hydroxylation.  7:  Aminocarboxymuconate  semialdehyde
decarboxylase.  8:  3-Hydroxyanthranilic  acid  oxygenase.  9:  Quinolinic  acid
phosphoribosyltransferase.
Figure 2. Possibilities for neuroprotection in the KP
Figure Legend:
I: Prodrug concept. II: Metabolic concept. III: KYNA analogue concept. IV: Nanotechnology
concept. 1: α7nACh receptor. 2: AMPA receptor. 3: NMDA receptor. 4: Extrasynaptic NMDA
receptor
From the periphery, only L-Trp, L-KYN and 3HK can be transported through the blood-brain
barrier (BBB) to reach the central nervous system (CNS). In the CNS, the main sources of the
neurotoxic  QUIN are  the  microglias  and the  macrophages.  This  metabolite  is  an  NMDA
receptor agonist, which can largely overactivate these receptors and cause neuronal damage.
In  the  astrocytes,  the  KP is  not  complete,  because  they  do  not  possess  KMO,  and  they
therefore  favour  the  formation  of  neuroprotective  KYNA.  In  the  prodrug  concept,  the
administration of L-KYN and KMO inhibitors increases the availability of L-KYN within the
CNS,  resulting  in  increased KYNA concentration  in  the  astrocytes.  After  release,  KYNA
exerts preferential inhibition on extrasynaptic NMDA and α7nACh receptors, but it does not
influence the AMPA and the synaptic NMDA receptors. In the KYNA analogue concept, 4-Cl-
KYN uses the same transporter and undergoes the same enzymatic mechanisms as L-KYN. In
the astrocytes, 4-Cl-KYN is transformed into 7-Cl-KYNA. 4-Cl-KYN is a precursor of the
3HAO inhibitor,  4-chloro-3-hydroxyanthranilic  acid.  In  the  KYNA analogue  concept,  the
KYNA analogues  can  cross  the  BBB more  easily  than  KYNA,  and  enhance  the  KYNA
concentration  within  the  CNS.  The  enzyme  inhibitors  (inhibitors  of  KMO,  3HAO  and
kynureninase)  concept  is  a  promising  pharmacological  tool,  shifting  the  pathway  to  the
neuroprotective compounds. The nanotechnology concept is a new approach with which to
enhance  the  neuroprotective  metabolite  concentrations  within  the  CNS  through  easier
transport across the BBB.
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